Effect of Cinnovex on Patients Suffering from Relapsing- Remitting Multiple Sclerosis

Yaser Esmaeilzadeh Chenijani, Amir Reza Ghayeghran

Abstract


Introduction: Multiple Sclerosis is an inflammatory (MS) disease of the central nervous system recognized as it demyelinates the brain and spinal cord. Much attempts have been taken to control and cure this decease among them Interferons have been widely used during recent two decades. Therefore, the present research aims to examine the effect of Cinnovex on patients have used it compared with the similar medicine Avonex.

Methods: This clinical randomized trial was performed in order to test the effect of Cinnovex impact on clinical symptoms of patients suffering from relapsing- remitting multiple sclerosis (MS) at Poursina hospital in Rasht in 2007 for one year. Patients were divided into three 40 subject groups receiving Cinnovex, Avonex and a control group. The patients’ EDSS and disease relapse were measured at the beginning and at the end of the test. The data analyzed by SPSS 20. P < 0.05 was considered statistically significant.

Results: There was no significant difference between EDSS of patients at the beginning of the study (1.95 ± 1.08) and EDSS of patients after one year experiment (1.97 ± 1.36). Also, based relapse (1.4 ± 0.7) decreased (P < 0.01) and a significant variance was found between EDSS of the patients received Cinnovex (1.97 ± 1.36) and the control group (3.06 ± 1.8) after one year (P < 0.001). In addition, Cinnovex and Avonex effects did not show a meaningful difference with each other.

Conclusions: It seems that Cinnovex can prevent from relapse and progress of EDSS of relapsing- remitting MS patients.


Full Text:

PDF

References


Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006;354:942-55. http://www.ncbi.nlm.nih.gov/pubmed/16510748

Kurtzke JF. Epidemiologic contributions to multiple sclerosis: an overview. Neurology. 1980;30:61-79. http://www.ncbi.nlm.nih.gov/pubmed/6993993

Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol. 1994;36 Suppl 2:S180-93. http://www.ncbi.nlm.nih.gov/pubmed/7998787

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-61. http://www.ncbi.nlm.nih.gov/pubmed/8469318

Paty D, Li D. IFNB multiple sclerosis study group: Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology. 1993;43:662-7.

Etemadifar M, Maghzi AH, Hoseinzadeh A. Comparing side effects of cinnovex with avonex in relapsing remitting multiple sclerosis patients. Journal of Isfahan Medical School. 2009;27:93-101.

Arnason BG. Interferon beta in multiple sclerosis. Neurology. 1993;43:641-3. http://www.ncbi.nlm.nih.gov/pubmed/8469315

Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031-48. http://www.ncbi.nlm.nih.gov/pubmed/18035202

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453-60. http://www.ncbi.nlm.nih.gov/pubmed/11988242

Stuart WH, Cohan S, Richert JR, Achiron A. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology. 2004;63:S19-27. http://www.ncbi.nlm.nih.gov/pubmed/15596732

Group IMSS. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology. 2001;57:S3-9. http://www.ncbi.nlm.nih.gov/pubmed/11902592




DOI: http://dx.doi.org/10.20286/nova-jmbs-040467

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Nova Journal of Medical and Biological Sciences ISSN 2292-793X (Online) Published by Nova Pub inc.

Nova Explore Publications
is a member of CrossRef.
DOI Prefix: 10.20286